Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by BioNxt Solutions Inc.

News headline image
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
News headline image
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
From BioNxt Solutions Inc.
Via ACCESS Newswire
Tickers BNXTF CSE:BNXT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.